Combination Therapy With Fenofibrate and Rosiglitazone Paradoxically Lowers Serum HDL Cholesterol-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination Therapy With Fenofibrate and Rosiglitazone Paradoxically Lowers Serum HDL Cholesterol

Published:2004-09-01 Issue:9 Volume:27 Page:2241-2242
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Normén Lena¹²,Frohlich Jiri²³,Montaner Julio⁴,Harris Marianne⁴,Elliott Tom⁵,Bondy Greg²³

Affiliation:

1. Canadian HIV Trials Network, Pacific Region, Vancouver, British Columbia, Canada

2. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada

3. Healthy Heart Program, St. Paul’s Hospital, Vancouver, British Columbia, Canada

4. BC Centre for Excellence of HIV/AIDS, St. Paul’s Hospital, Vancouver, British Columbia, Canada

5. Department of Endocrinology, University of British Columbia, Vancouver, British Columbia, Canada

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/27/9/2241/563962/zdc00904002241.pdf

Reference6 articles.

1. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86:280–288, 2001

2. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088–2093, 1998

3. Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34:155–162, 1998

4. Baldwin SJ, Clarke SE, Chenery RJ: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48:424–432, 1999

5. Minnich A, Tian N, Byan L, Bilder G: A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 280:E270–E279, 2001

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Co-Administration of Conjugated Linoleic Acid and Rosiglitazone Increases Atherogenic Co-Efficient and Alters Isoprenaline-Induced Vasodilatation in Rats Fed High Fat Diet;Physiological Research;2018-10-25

2. Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone;Molecular & Cellular Proteomics;2016-03

3. Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial;Diabetes Care;2014-02-11

4. Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin;Lipids in Health and Disease;2011

5. High-performance Liquid Chromatographic Analysis of Pioglitazone, Gliquidone, Rosuvastatin and Simvastatin in Formulations and Human Serum;Chinese Journal of Chemistry;2010-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3